Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features

• Material Type: 博士論文
• Title: Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features
• Author/Editor: Kobayashi, Kyoko
• Author Heading: Kobayashi, Kyoko
• Publication, Distribution, etc.: 三重大学
• Publication Date: 2016-07-20
• Publication Date (W3CDTF): 2016-07-20
• Degree grantor/type: 三重大学
• Date Granted: 2016-07-20
• Date Granted (W3CDTF): 2016-07-20
• Dissertation Number: 乙医学第998号
• Degree Type: 博士(医学)
• Conferring No. (Dissertation): 乙医学第998号
• Text Language Code: eng
• Alias of Author: コバヤシ, キョウコ; 小林, 恭子
• Subject Heading: CD5; diffuse large B‐cell lymphoma; LMO3; SH3BP5; SNAP25
• Target Audience: 一般
• Note (General): application/pdf; Diffuse large B-cell lymphoma (DLBCL) is clinicopathologically and genetically heterogeneous with variable clinical outcomes. We previously identified signature genes overexpressed in CD5-positive(CD5+) DLBCL, which is a poor prognostic subgroup of DLBCL. To elucidate the clinical significance of the protein expression of the signature genes overexpressed in CD5+ DLBCL with regard to all DLBCL, not otherwise specified (NOS), 10 genes (SH3BP5, LMO3, SNAP25, SYT5, SV2C, CABP1, FGF1, FGFR2, NEUROD1, and SYN2) were selected and examined immunohistochemically with samples from 28 patients with DLBCL, NOS. Only three protein expressions, SH3BP5, LMO3, and SNAP25, were detected in DLBCL cells and then analyzed further with samples from 187 patients with DLBCL, NOS. The SH3BP5, LMO3, and SNAP25 proteins were expressed in 60% (103/173), 34% (59/175), and 46% (77/168) of DLBCL patients, respectively. These protein expressions were associated with CD5 expression, and only SH3BP5 was frequently expressed in activated B-cell-like DLBCL (P = 0.046). Compared to the SH3BP5-negative group, the SH3BP5+ group was correlated with elderly onset (＞60 years, P = 0.0096) and advanced-stage disease (stage III/IV, P = 0.037). The LMO3+ group showed a worse performance status (＞1, P = 0.0004). The SH3BP5+ group and the LMO3+ group had significantly worse overall survival than the negative groups (P = 0.030, 0.034; respectively) for the entire group. In a subgroup analysis of patients treated with rituximab-containing chemotherapy, there was no significant difference between groups. To the best of our knowledge, this is the first report showing the protein expressions of SH3BP5, LMO3, and SNAP25 in DLBCL cells and their clinical significance in patients with DLBCL. The SH3BP5 and LMO3 protein expressions are associated with the baseline clinical characteristics of DLBCL.; 本文 / Department of Hematology and Oncology, Mie University Graduate School of Medicine; 10p
• DOI: info:doi/10.1002/cam4.753; https://doi.org/info:doi/10.1002/cam4.753
• Persistent ID (NDL): info:ndljp/pid/10993782; https://dl.ndl.go.jp/pid/10993782
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2017-12-04T02:02:48+09:00
• Date Created (W3CDTF): 2017-11-07
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10076/00017103; https://mie-u.repo.nii.ac.jp/records/11459
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2023-12-15 再収集